紫杉醇同步放化疗在中晚期乳腺癌细胞增殖抑制中的作用及并发症预防对策

Effect of paclitaxel in combined with chemoradiotherapy in inhibiting the cell proliferation in the middle and later stage of breast cancer and measures to prevent complications

目的:研究紫杉醇同步放化疗在中晚期乳腺癌细胞增殖抑制中的作用及并发症预防对策。方法:选取本院收治的74例中晚期乳腺癌患者。根据抽取法分为试验组和对照组,每组37例。对照组采取常规放疗,试验组使用紫杉醇同步放化疗。比较两组治疗前后MCF-7细胞BaxmRNA、p53的表达水平,分析患者的生活质量改善情况、临床疗效及不良反应。结果:试验组治疗后总缓解率明显高于对照组,差异具有统计学意义(P<0.05);治疗后,试验组的MCF-7细胞Bax mRNA和p53表达明显高于对照组,差异具有统计学意义(P<0.05);试验组总的生活质量提高率高于对照组,差异具有统计学意义(P<0.05);试验组和对照组的不良反应率比较,差异无统计学意义(P>0.05)。结论:紫杉醇同步放化疗能有效抑制中晚期乳腺癌细胞MCF-7的增殖,提高患者的生存质量,临床疗效良好。

Objective:To study the effect of paclitaxel in combined with chemoradiotherapy in inhibiting the cell proliferation of breast cancer in the middle and later stage and the complication prevention measures.Methods:A total of 74 patients with middle-advanced stage breast cancer who were admitted in our hospital were included in the study and divided into the experiment group and the control group according to the extraction method with 37 cases in each group.The patients in the control group were given the conventional radiotherapy,while the patients in the experiment group were given paclitaxel in combined with chemoradiotherapy.The expression levels of BaxmRNA and p53 of MCF-7cell before and after treatment in the two groups were compared.The improvement of living qualities,the clinical efficacy,and the adverse reactions in the two groups were analyzed.Results:After treatment,the overall response rate in the experiment group[72.97%(27/37)]was significantly higher than that in the control group[40.54%(15/37)](P<0.05).After treatment,the expression levels of BaxmRNA andp53of MCF-7cell in the experiment group were significantly higher than those in the control group(P<0.05).The increasing rate of living qualities in the experiment group [62.16%(23/37)]was significantly higher than that in the control group[18.92%(7/37)](P<0.05).The occurrence rates of adverse reactions in the experiment group and the control group were[13.51%(5/37)]and[16.22%(6/37)],respectively showing no significant difference(P>0.05).Conclusions:Paclitaxel in combined with chemoradiotherapy in the treatment of middle-advanced stage breast cancer can effectively inhibit the proliferation of MCF-7,and enhance the living qualities,with a preferable clinical efficacy.